What this is
- is emerging as a potential treatment for in palliative care.
- Despite its promise, access to this therapy is limited in Canada due to regulatory barriers and lack of trained professionals.
- A forum was held to discuss actionable steps for improving access and responsible use of .
- This report outlines 16 recommendations aimed at addressing key topics such as patient eligibility, regulatory frameworks, and public awareness.
Essence
- shows promise for alleviating in palliative care, but access remains constrained by regulatory and logistical challenges. A recent forum produced recommendations to enhance equitable access and responsible implementation.
Key takeaways
- can significantly alleviate symptoms of anxiety and depression in up to 80% of selected patients with life-threatening illnesses. This therapy offers a potential alternative for those suffering from .
- Access to in Canada is limited due to its classification as a controlled substance and the requirement for case-by-case approval. This creates delays that are detrimental to palliative patients.
- The forum generated 16 recommendations across six key topics, including improving patient eligibility criteria and enhancing public awareness. These recommendations aim to facilitate the responsible integration of psilocybin therapy into palliative care.
Caveats
- The final recommendations were not reviewed by all forum participants, which may have led to the exclusion of certain perspectives. However, consensus was reached among a subset of participants.
- Specific steps to streamline the complex access procedures for psilocybin-assisted therapy were not discussed in detail during the forum, highlighting a gap in the recommendations.
Definitions
- psilocybin-assisted psychotherapy: A therapeutic approach combining psilocybin, a psychedelic compound, with psychotherapy to alleviate psychological distress.
- existential distress: A psychological condition characterized by feelings of anxiety and despair related to the meaning of life and impending death.
Simplified
Introduction
Existential distress is a complex condition experienced by many individuals facing a life-threatening illness.1–3 This distress encompasses symptoms of depression, anxiety, demoralization, and loss of meaning.1,4 Common interventions to alleviate this distress in palliative care include pharmacotherapy (notably antidepressants and anxiolytics), psychotherapy, and spiritual support.1,5–7 Unfortunately, the effectiveness of these approaches remains inconsistent, with some studies showing limited benefits in alleviating this distress or highlighting accessibility challenges, leaving many patients suffering with little relief.1,4,8–14 Given the limitations of conventional treatments, it is crucial to explore alternatives to improve the well-being and quality of life of those facing persistent, unbearable suffering, whether they choose to die naturally or with medical assistance.15–17 Recently, a new treatment has offered hope to individuals suffering from existential distress: psilocybin-assisted psychotherapy.4,18–23
Several clinical studies have demonstrated that a single dose of psilocybin, combined with a few psychotherapy sessions, can significantly and sustainably alleviate symptoms of anxiety and depression in individuals with life-threatening illnesses who experience existential distress or demoralization.4,18–20,23,24 These benefits could improve the condition of up to 80% of selected patients suffering from end-of-life distress.23,24 In clinical studies, psilocybin-assisted therapy is generally well tolerated, with most adverse effects being mild to moderate and transient. Common side effects include nausea, headaches, transient increases in blood pressure, and psychological reactions such as anxiety or confusion, which typically resolve without medical intervention. In studies on treatment-resistant depression, serious adverse events are rare (<5%) but may include prolonged psychological distress or exacerbation of underlying psychiatric conditions, particularly in individuals with a history of psychotic disorders.4,18,25,26
Commonly used exclusion criteria in clinical studies include a personal or family history of psychotic disorders, bipolar I disorder, severe personality disorders, epilepsy, and significant cardiovascular conditions. Pregnant or breastfeeding individuals and those taking serotonergic medications are also typically excluded. While these criteria are designed to ensure patient safety, further research is needed to better assess the risk-benefit profile in populations with life-threatening illnesses, where the potential therapeutic benefits may outweigh certain risks.4,27 The concurrent use of psilocybin and serotonergic medications presents potential challenges.28–30 As many patients considering psilocybin-assisted psychotherapy may already be receiving antidepressants, careful consideration of potential drug interactions is needed before initiating treatment, including assessing the risk of serotonin syndrome, the possible attenuation of psilocybin’s therapeutic effects, and the appropriate timing for tapering or discontinuing antidepressants if necessary. Small studies suggest that continuing Selective Serotonin Reuptake Inhibitors during psilocybin therapy appears safe and effective,31 while discontinuation might diminish treatment response.28
Internationally, psilocybin-assisted psychotherapy has been integrated into the health care systems of some jurisdictions, such as Switzerland, Australia, parts of the United States, and Canada.32,33 Each country is taking a different approach, with Australia leading in regulatory integration, Switzerland and Canada favoring a medical authorization approach, requiring case-by-case approval by their respective federal health agencies Table 1. In the United States, certain states have legalized psilocybin for therapeutic use, as in Oregon and Colorado, with the latter having a dedicated clinical facilitator license. Since January 2022, a legislative amendment to the Special Access Program has allowed Canadian physicians to request access to psilocybin for patients with end-of-life distress or major depressive disorder who have not responded to conventional therapeutic approaches.34 Furthermore, in December 2022, Quebec became the first Canadian province to approve reimbursement for psilocybin-assisted psychotherapy through the RAMQ (Quebec’s government health care insurance system).35
Despite the relaxation of legislative and regulatory measures, access to psilocybin-assisted psychotherapy remains limited in Canada.36 Legally, psilocybin is designated as a “controlled substance” under the Controlled Drugs and Substances Act (CDSA) and available only through clinical trials, an exemption under the CDSA or the Special Access Program under the Food and Drug Regulations. Notably, very few physicians and therapists have been trained on how to offer it to their patients. Additionally, when these requests are submitted to Health Canada, they must be evaluated on a case-by-case basis, resulting in administrative burdens and delays that palliative patients cannot afford.36 Consequently, some desperate individuals resort to experiencing psilocybin in underground settings or self-medicating despite the associated risks.37 Furthermore, there is limited awareness of the availability of this approach among potential candidates, particularly those from rural regions and minority groups.38–40 Logistical aspects, such as the development of dedicated spaces and the availability of qualified personnel, also present challenges for health care settings.
Psilocybin-assisted psychotherapy is a promising intervention that can complement the therapeutic arsenal of palliative care, aiming to provide individuals with the best possible quality of life during the period leading up to their death, whether through natural causes or medical assistance in dying. The province of Quebec, Canada, has the highest rate of medical assistance in dying globally, with 6.8% of deaths in 2023 occurring through this process.41 Since existential distress is one of the main reasons for requesting medical assistance in dying, there is significant social relevance in seeking measures to improve access to this therapy, as was recently recommended by the Special Joint Committee on Medical Assistance in Dying in Canada (2023):
In an effort to actively contribute to societal discussions and to derive relevant recommendations on these issues, the P3A team (Psilocybin at End of Life: Audacity, Acceptability, Access) organized a forum with the goal of identifying actionable steps toward responsible use and equitable access to psilocybin-assisted psychotherapy for existential distress in individuals suffering from life-threatening illnesses. This article outlines the methodology used, presents the forum results, and highlights the key recommendations emerging from the discussions and deliberations.
| Country | Legal status | Procedural approach | Unique aspects |
|---|---|---|---|
| Canada | Limited federal access via exemptions and Special Access Program (SAP) | Special authorization via Health Canada on a case-by-case basis or through clinical trials | Centralized system, slow and restrictive process |
| United States | State-level initiatives, federal prohibition outside of research | Access through clinical trials or state-led programs | State-based models (e.g., Colorado), fragmented access |
| Switzerland | Physician-authorized access | Special authorization via the Federal Office of Public Health | Streamlined medical approach, advanced research |
| Australia | National regulation for psychiatry | Prescription allowed by authorized psychiatrists or through clinical trials | First country to reclassify psilocybin for depression |
P3A Forum Overview
Planning and Scientific and Organizing Committee setup
Planning for the P3A Forum began in January 2023 with the establishment of an interdisciplinary Scientific and Organizing Committee (M.D., S.L.C., H.F., O.N., J.F.S., D.T., and J.S.F.). This committee was tasked with developing the event’s scientific program, identifying stakeholders to invite, and outlining a partnership plan. The committee held 11 virtual meetings leading up to the forum. From the outset, the committee agreed that partners invited to contribute financially to the event should not have any real, potential, or apparent conflicts of interest with the forum’s topic and should be ecologically and socially responsible organizations, associations, or companies. The list of partners is available in the Acknowledgments section.
Participant recruitment and invitation process
A total of 83 invitations were sent via email to professional and patient associations, health care professionals, researchers, and policymakers identified for their expertise in palliative care in Quebec. Among them, 69 (83%) accepted the invitation. All declined invitations were attributed to scheduling conflicts, except for one organization that felt uneasy about the subject matter. Fifty-seven individuals of those who accepted the invitation (83%) attended the event, with absences attributed to health issues, travel difficulties, or last-minute scheduling conflicts. Among them, 25 (44%) were male and 32 (56%) were female. Most participants (70%) were from academic settings or health care providers, while the remaining included patients/advocacy groups, representatives from clinics/hospitals/health systems, and policymakers (Table 2).
| Characteristics | (%)N |
|---|---|
| Sex | |
| Male | 25 (43.9) |
| Female | 32 (56.1) |
| Stakeholder categorya | |
| Academic (researchers, research staff, trainees) | 22 (38.6) |
| Health care providers (psychiatrists, medical specialists, family physicians, nurses, etc.) | 18 (31.6) |
| Patients/Advocacy organizations (patients, caregivers, palliative care organizations, etc.) | 8 (14.0) |
| Clinic/Hospital/Health system representatives (managers) | 3 (5.3) |
| Policymakers | 6 (10.5) |
Proceedings: Keynote, workshop, and plenary sessions
Approximately two months before the forum, those accepting the invitation received peer-reviewed articles, lay documents from Canadian government sources, and a link to a national television report on psilocybin-assisted psychotherapy.42
The P3A Forum was held in person in Quebec City, Canada, on March 22, 2024. The first part of the day consisted of expert presentations that provided an overview of the professional, legal, ethical, regulatory, and organizational issues related to psilocybin-assisted psychotherapy for individuals suffering from existential distress. Testimonials from individuals (F.M. and R.F.) who had undergone the therapy were also shared during this period. The presentations were conducted in French and English. There was no simultaneous translation service provided. Questions and discussions could take place in both languages, with the moderator translating discussions as needed. The moderator was independent of the P3A team and had no direct involvement in the field of psilocybin.
In the afternoon, attendees were divided into small groups for workshops. Each group discussed one of seven predetermined themes, the goal being to come up with concrete actions to improve access to and delivery of psilocybin-assisted psychotherapy for individuals suffering from existential distress (Table 3). Group assignments were determined in advance by the committee to ensure representation across disciplines and roles. Each group was moderated by one of the authors (M.D., S.L.C., H.F., O.N., J.F.S., D.T., and J.S.F.), with a graduate student assigned to take notes of the discussions.
A 90-minute plenary session, facilitated by the moderator, followed. During this session, a representative from each small group first summarized the key points agreed upon during the workshops. These points were then the subject of a group discussion aimed at building a consensus on the priority actions to improve access to psilocybin-assisted psychotherapy for alleviating existential distress in individuals with life-threatening illnesses. Notes were also taken during the plenary session. The session concluded with a verbal summary provided by the event moderator.
| Questions | |
|---|---|
| Patient eligibility and equity | Should eligibility criteria for PAT be reviewed to ensure more equitable access? If so, how? If not, why not? |
| Regulatory framework and respect for autonomy | How can we reconcile the regulatory framework for PAT with respect for patient autonomy? |
| Logistical and organizational aspects | How can healthcare organizations prepare for expanded access to PAT? |
| Professional training | Which professionals should be able to offer PAT, and how should they be trained? |
| Professional education | Should all healthcare professionals involved in palliative care have a minimum knowledge of PAT? If so, how can this be achieved? |
| Public awareness and information | How can we raise awareness and inform the general population about PAT, and thus help demystify this psychedelic substance? |
| Research | How can research facilitate PAT implementation in palliative care? |
Deliberation analysis and recommendation development
Notes taken throughout the day and during the workshops were transcribed and then independently summarized by two graduate students. While no formal coding was performed, these summaries aimed to distill the key points raised during the discussions. Based on these notes, two authors (M.D. and S.L.C.) drafted preliminary recommendations for each of the themes discussed during the sessions. The draft recommendations were then shared online with all authors of this article. Through multiple rounds of asynchronous review and discussion via email and online platforms, feedback was collected, and revisions were made to refine the recommendations. The iterative review continued until a consensus was reached among the authors.
Recommendations
Patient eligibility and equity
Regulatory framework and respect for autonomy
Logistical and organizational aspects
Professional education and training
Public awareness and information
Research
Conclusions
Considering the growing public interest, medical enthusiasm, and the gradual easing of legislative barriers, psilocybin-assisted psychotherapy is expected to gain wider acceptance. By offering individuals with life-threatening illnesses a means to temporarily ease the anguish of unbearable suffering and impending death while enhancing their quality of life, it may become an increasingly sought-after option. In a context where medical assistance in dying is widely accessible in Quebec, psilocybin-assisted psychotherapy could offer an alternative or complementary approach that redefines palliative care as a space for living rather than solely for end-of-life care. It seems ethically important that individuals who may choose medical assistance in dying, mainly as an end to their existential suffering, have the opportunity to consider psilocybin-assisted psychotherapy before they make such a choice.
A key challenge in implementing psilocybin-assisted therapy in palliative care is the complexity of current access procedures, which may not align with the limited time many patients have. While this issue was acknowledged during the forum, specific steps to streamline the process were not discussed in detail. Given the regulatory nature of these procedures, addressing this challenge will require further collaboration with policymakers and relevant health authorities to develop more efficient pathways that ensure timely and equitable access for eligible patients.
The costs associated with psilocybin-assisted therapy also represent an important consideration for its potential integration into the health care system. In Canada’s publicly funded universal health care system, ensuring equitable access to new therapies requires careful assessment of cost-effectiveness, funding mechanisms, and reimbursement policies. Future discussions should involve policymakers, health care administrators, and researchers to explore sustainable funding models that align with the principles of accessibility and universality in the Canadian health care system.
Although the recommendations in this article are specifically aimed at providing guidance for the successful implementation of psilocybin-assisted psychotherapy in palliative care, addressing regulatory barriers to facilitate research in this field is equally important. Ultimately, any changes in the regulatory status of psilocybin will be driven by rigorous formal research.
Given the lack of evidence regarding the efficacy of psilocybin microdosing, this topic was not specifically addressed during the forum and therefore falls outside the scope of these recommendations.43 The potential therapeutic applications of psilocybin microdosing in palliative care are an emerging area of interest needing further investigation.44
A potential limitation is that the final recommendations were not reviewed by all forum participants, which may have led to the inadvertent exclusion of certain perspectives or nuances discussed during the workshops and plenary sessions. However, it is important to note that the recommendations were drafted until the consensus by 12 of the 57 (21%) forum participants, including those who moderated the group sessions. Through this collaborative process, we are confident that the final recommendations are aligned with the discussions at the forum while achieving clarity and coherence.
As is the case in many other jurisdictions, we recognize that there are challenges in accessing health care services in Quebec. Like any innovative treatment, psilocybin-assisted psychotherapy is not exempt from these challenges. Our recommendations aim to ensure that this new therapeutic approach reduces health disparities rather than amplifying them.